Archive for the ‘
Pharma Business ’ Category
Thursday, February 11th, 2010
This month, General Motors took advantage of Toyota's recall misfortune and public relations silence by revealing a shiny new purchase-and-lease incentive program targeting Toyota and Lexus customers. GM's program running through February, allows Toyota owners who end their lease to receive up to $1,000 off a new or leased GM ...
Posted in
Adwise, DTC advertising, Legal actions, Manny Awards, Pharma Business, Sales & Marketing, Sales force effectiveness, Uncategorized, blogs |
No Comments »
Friday, January 22nd, 2010
Up-to-date contact information for healthcare professionals and prescribers is critical asset to life sciences companies. CRM provider Cegedim Dendrite serves that need via its OneKey Services, a customer data management and integration solution. With the recent acquisition of U.S. healthcare data provider SK&A Information Services Inc., Cegedim Dendrite executives hope ...
Posted in
Pharma Business, Technology |
No Comments »
Tuesday, January 19th, 2010
A 9-year-old boy obsesses over his mayoral approval rating within the online world of Sim City 2000. A 13-year-old girl misses dinner to attend a board meeting as her World of Warcraft compatriots debate the merits of a guild merger. Speaking today at a panel discussion hosted by ProtonMedia and ...
Posted in
Economy, Pharma Business, Pharmaceutical operations, Professional education, Sales force effectiveness, Technology, e-Marketing |
3 Comments »
Wednesday, January 13th, 2010
As J.P. Morgan’s 28th Annual Healthcare Conference in San Francisco winds down, Kevin Butler of Heritage Partners International checks in with one final report.
Although there is guarded optimism all around, Mr. Butler believes that we can expect any shock to the system to cause major trauma. “Perhaps if ee get ...
Posted in
Pharma Business, Pharmaceutical operations |
1 Comment »
Tuesday, January 12th, 2010
Kevin Butler of Heritage Partners International has reported in with his Tuesday afternoon update from J.P. Morgan’s 28th Annual Healthcare Conference in San Francisco.
In his previous update, Mr. Butler reported good spirits among the attendees. However, there seems to be an East Coast/West Coast divide.
“The West Coast people seem much ...
Posted in
Pharma Business, Pharmaceutical operations |
1 Comment »
Tuesday, January 12th, 2010
Frequent Med Ad News contributor Kevin Butler of Heritage Partners International is in attendance at J.P. Morgan’s 28th Annual Healthcare Conference in San Francisco. Mr. Butler will be checking in routinely with updates from the event, which brings together industry leaders and technology and service providers.
Upon arriving yesterday, January 11, ...
Posted in
Pharma Business, Pharmaceutical operations |
1 Comment »
Monday, December 21st, 2009
Healthcare reform has taken a major step forward as the Democratic caucus voted to curtail debate on the bill. The final vote on the Senate’s version of healthcare reform could come by Christmas, at which point the Senate must then draft a compromise with the House, which approved its own ...
Posted in
Legal actions, Pharma Business, Pharmaceutical operations, Sales & Marketing |
1 Comment »
Wednesday, December 2nd, 2009
Healthcare reform and changing business models could have profound tax implications for the pharmaceutical industry.
Yesterday, PricewaterhouseCoopers announced a new report called “Pharma 2020: Taxing times ahead - Which path will you take?”, which looks at the forces that are driving up the effective tax rate for pharmaceutical and life sciences ...
Posted in
Economy, Legal actions, Pharma Business, Pharmaceutical operations |
1 Comment »
Friday, May 15th, 2009
On April 26, the Acting Secretary of HHS declared a public health emergency related to the current outbreak of swine flu (now designated “novel 2009 H1N1”). In response to this public health emergency, the CDC requested Emergency Use Authorization for the use of Tamiflu and Relenza for the treatment and ...
Posted in
Pharma Business |
No Comments »
Monday, March 9th, 2009
So, Merck & Co. and Schering-Plough Corp. have formed a definitive merger agreement under which Merck and Schering-Plough will merge under the name Merck in a deal valued at $23.61 per share, or $41.1 billion. Friend of Med Ad News, Mike Luby, has kindly shared his thoughts on the proposed ...
Posted in
Pharma Business |
No Comments »
|
|
